布地奈德口腔分散片治疗嗜酸性食管炎的实际疗效：耐心和教育的重要性。

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2025-05-14 DOI:10.1111/apt.70197

Sarah Taylor,Emily Barwick,Varan Perananthan,Nikita Parkash,Sarah Lucas,Ayushi Chauhan,Catherine Yu,Katrina Tan,Gloria Sepe,Mani Suleiman,Diana Lewis,Chamara Basnayake,Hamish Philpott,Sanjay Nandurkar,Rebecca Burgell,Mayur Garg

{"title":"布地奈德口腔分散片治疗嗜酸性食管炎的实际疗效：耐心和教育的重要性。","authors":"Sarah Taylor,Emily Barwick,Varan Perananthan,Nikita Parkash,Sarah Lucas,Ayushi Chauhan,Catherine Yu,Katrina Tan,Gloria Sepe,Mani Suleiman,Diana Lewis,Chamara Basnayake,Hamish Philpott,Sanjay Nandurkar,Rebecca Burgell,Mayur Garg","doi":"10.1111/apt.70197","DOIUrl":null,"url":null,"abstract":"Budesonide orodispersible tablets (BOT) have been shown to be efficacious for eosinophilic oesophagitis (EoE) in clinical trials. This study evaluated the real-world effectiveness of BOT in a retrospective cohort of 94 patients across six tertiary centres. 61% of patients achieved histological remission and 39% clinicohistological remission following induction therapy. Adverse events were reported by 16% of patients and 17% were noted to have incorrect technique of administration. BOT was demonstrated to have lower rates of clinicohistological remission in real-world practice than reported in clinical trials, largely due to incorrect technique and cessation due to adverse events.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"35 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and Education.\",\"authors\":\"Sarah Taylor,Emily Barwick,Varan Perananthan,Nikita Parkash,Sarah Lucas,Ayushi Chauhan,Catherine Yu,Katrina Tan,Gloria Sepe,Mani Suleiman,Diana Lewis,Chamara Basnayake,Hamish Philpott,Sanjay Nandurkar,Rebecca Burgell,Mayur Garg\",\"doi\":\"10.1111/apt.70197\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Budesonide orodispersible tablets (BOT) have been shown to be efficacious for eosinophilic oesophagitis (EoE) in clinical trials. This study evaluated the real-world effectiveness of BOT in a retrospective cohort of 94 patients across six tertiary centres. 61% of patients achieved histological remission and 39% clinicohistological remission following induction therapy. Adverse events were reported by 16% of patients and 17% were noted to have incorrect technique of administration. BOT was demonstrated to have lower rates of clinicohistological remission in real-world practice than reported in clinical trials, largely due to incorrect technique and cessation due to adverse events.\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2025-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.70197\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.70197","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

布地奈德或分散片（BOT）在临床试验中已被证明对嗜酸性食管炎（EoE）有效。本研究对来自6个三级中心的94名患者进行回顾性队列研究，评估了BOT的实际有效性。诱导治疗后，61%的患者达到组织学缓解，39%的患者达到临床组织学缓解。16%的患者报告了不良事件，17%的患者指出有不正确的给药技术。在现实世界的实践中，BOT的临床组织学缓解率比临床试验中报道的要低，这主要是由于不正确的技术和由于不良事件而停止。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and Education.

Budesonide orodispersible tablets (BOT) have been shown to be efficacious for eosinophilic oesophagitis (EoE) in clinical trials. This study evaluated the real-world effectiveness of BOT in a retrospective cohort of 94 patients across six tertiary centres. 61% of patients achieved histological remission and 39% clinicohistological remission following induction therapy. Adverse events were reported by 16% of patients and 17% were noted to have incorrect technique of administration. BOT was demonstrated to have lower rates of clinicohistological remission in real-world practice than reported in clinical trials, largely due to incorrect technique and cessation due to adverse events.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.